Does OLMESARTAN MEDOXOMIL Cause Product packaging quantity issue? 6 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Product packaging quantity issue have been filed in association with OLMESARTAN MEDOXOMIL (OLMESARTAN MEDOXOMIL). This represents 0.1% of all adverse event reports for OLMESARTAN MEDOXOMIL.
6
Reports of Product packaging quantity issue with OLMESARTAN MEDOXOMIL
0.1%
of all OLMESARTAN MEDOXOMIL reports
0
Deaths
2
Hospitalizations
How Dangerous Is Product packaging quantity issue From OLMESARTAN MEDOXOMIL?
Of the 6 reports, 2 (33.3%) required hospitalization, and 1 (16.7%) were considered life-threatening.
Is Product packaging quantity issue Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OLMESARTAN MEDOXOMIL. However, 6 reports have been filed with the FAERS database.
What Other Side Effects Does OLMESARTAN MEDOXOMIL Cause?
Sprue-like enteropathy (3,482)
Gastrooesophageal reflux disease (1,819)
Acute kidney injury (1,587)
Weight decreased (1,569)
Haemorrhoids (1,316)
Diarrhoea (1,300)
Hiatus hernia (938)
Dizziness (885)
Large intestine polyp (839)
Constipation (796)
What Other Drugs Cause Product packaging quantity issue?
LEUPROLIDE (523)
ALBUTEROL (431)
BUDESONIDE\FORMOTEROL (301)
FENTANYL (286)
BUPRENORPHINE (225)
CYCLOSPORINE (206)
ESTRADIOL (201)
BIMATOPROST (177)
RIVAROXABAN (174)
EXENATIDE (154)
Which OLMESARTAN MEDOXOMIL Alternatives Have Lower Product packaging quantity issue Risk?
OLMESARTAN MEDOXOMIL vs OLMETEC
OLMESARTAN MEDOXOMIL vs OLODATEROL
OLMESARTAN MEDOXOMIL vs OLODATEROL\TIOTROPIUM
OLMESARTAN MEDOXOMIL vs OLOPATADINE
OLMESARTAN MEDOXOMIL vs OLUTASIDENIB